UK's NICE backs methylphenidate for ADHD and hep C combination therapy

The National Institute for Clinical Excellence, which provides guidanceto the National Health Service in England and Wales on medicines based on cost-effectiveness, has recommended that methylphenidate be used as part of a treatment program for children with severe attention deficit hyperactivity disorder.

In the UK, only two medications are currently licensed for use in treating ADHD, those being methylphenidate and dexamphetamine. However, observes the NICE, physicians will sometimes prescribe tricyclic and other antidepressants for the condition. With the issuance of its guidance, health professionals are expected to take the NICE's recommendations into account when prescribing.

The cost of methylphenidate is around L200 ($290) per child per annum, assuming an average daily dose of 30mg, says the NICE, adding that the estimated annual cost, including assessment and follow-up, is expected to be around L500-L1,000 per child. It is believed that approximately 69,000 school-aged children (or 1%) in England and Wales satisfy diagnostic criteria for severe ADHD. However, around 48,000 are not currently receiving treatment with methylphenidate.